What does this research mean for the field?

Modulating AP-1 enables CAR T cells to establish an intratumoral stemlike reservoir and overcomes resistance to PD-1 blockade. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.CHALLENGES_CONSENSUS.

What question did this study set out to answer?

The study investigates how modifying AP-1 can improve CAR T cell effectiveness against PD-1 blockade in tumors.

March 8, 2026

Modulating AP-1 enables CAR T cells to establish an intratumoral stemlike reservoir and overcomes resistance to PD-1 blockade

Puntos clave

The study investigates how modifying AP-1 can improve CAR T cell effectiveness against PD-1 blockade in tumors.
Utilized murine models of lung cancer to observe CAR T cell responses.
Examined gene expression changes related to exhaustion and activation in CAR T cells.
Analyzed the impact of PD-L1 blockade on c-Jun and TCF1 levels in CAR T cells.
Overexpression of c-Jun increased intratumoral PD-1+ TCF1+ CAR T cells but did not prevent their exhaustion.
PD-L1 blockade restored c-Jun levels, significantly boosting CAR T cell numbers.
Near-complete tumor clearance was achieved with the combination of c-Jun upregulation and PD-L1 blockade.

Resumen

Chimeric antigen receptor T (CAR T) cell therapy has shown limited synergy with immune checkpoint inhibitors, but the mechanisms underlying resistance remain unclear. Stemlike T cells coexpressing programmed cell death protein 1 (PD-1) and T cell factor 1 (TCF1) mediate responses to PD-1-PD-L1 (programmed death ligand 1) blockade and are maintained by major histocompatibility complex (MHC)-dependent interactions with dendritic cells in lymphoid tissues. Because CAR T cells recognize intact antigen rather than peptide-MHC, their activation is restricted to tumors, potentially limiting maintenance of this critical subset. In murine models of lung cancer, CAR T cells down-regulated TCF1, became exhausted, and were not enhanced by PD-L1 blockade. Overexpression of the transcription factor c-Jun increased intratumoral PD-1+TCF1+ CAR T cells but did not prevent exhaustion, given that PD-1 induced posttranscriptional c-Jun down-regulation. PD-L1 blockade restored c-Jun levels, markedly increased CAR T cells, and enabled near-complete tumor clearance, revealing a mechanism by which MHC-independent CAR T cells can be engineered to overcome resistance to PD-1-PD-L1 blockade.

Me gusta

Guardar